These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8429830)

  • 61. Preimplantation embryos cooperate with oviductal cells to produce embryotrophic inactivated complement-3b.
    Tse PK; Lee YL; Chow WN; Luk JM; Lee KF; Yeung WS
    Endocrinology; 2008 Mar; 149(3):1268-76. PubMed ID: 18039777
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Staphylococcal Ecb protein and host complement regulator factor H enhance functions of each other in bacterial immune evasion.
    Amdahl H; Jongerius I; Meri T; Pasanen T; Hyvärinen S; Haapasalo K; van Strijp JA; Rooijakkers SH; Jokiranta TS
    J Immunol; 2013 Aug; 191(4):1775-84. PubMed ID: 23863906
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The binding of human complement proteins C5, factor B, beta 1H and properdin to complement fragment C3b on zymosan.
    DiScipio RG
    Biochem J; 1981 Dec; 199(3):485-96. PubMed ID: 6462133
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Regulation of the C3 nephritic factor stabilized C3/C5 convertase of complement by purified human erythrocyte C3b receptor.
    Daha MR; Kok DJ; Van Es LA
    Clin Exp Immunol; 1982 Oct; 50(1):209-14. PubMed ID: 6216999
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway.
    Fearon DT
    Proc Natl Acad Sci U S A; 1978 Apr; 75(4):1971-5. PubMed ID: 273923
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Role of fibrinogen in complement inhibition by streptococcal M protein.
    Horstmann RD; Sievertsen HJ; Leippe M; Fischetti VA
    Infect Immun; 1992 Dec; 60(12):5036-41. PubMed ID: 1452335
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Complement alternative pathway activation and control on membranes of human lymphoid B cell lines.
    Caudwell V; Porteu F; Calender A; Pangburn MK; Halbwachs-Mecarelli L
    Eur J Immunol; 1990 Dec; 20(12):2643-50. PubMed ID: 1702720
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Regulatory proteins for the activated third and fourth components of complement (C3b and C4b) in mice. II. Identification and properties of complement receptor type 1 (CR1).
    Kinoshita T; Lavoie S; Nussenzweig V
    J Immunol; 1985 Apr; 134(4):2564-70. PubMed ID: 3156184
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Factor I co-factor activity of CR1 overcomes the protective effect of IgG on covalently bound C3b residues.
    Fries LF; Prince GM; Gaither TA; Frank MM
    J Immunol; 1985 Oct; 135(4):2673-9. PubMed ID: 3161945
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Isolation and characterization of a 33,000-dalton fragment of complement Factor B with catalytic and C3b binding activity.
    Lambris JD; Müller-Eberhard HJ
    J Biol Chem; 1984 Oct; 259(20):12685-90. PubMed ID: 6567645
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The C3/C5 convertase of the alternative pathway of complement: stabilization and restriction of control by lanthanide ions.
    Fishelson Z; Müller-Eberhard HJ
    Mol Immunol; 1983 Mar; 20(3):309-15. PubMed ID: 6553181
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb.
    Fujita T; Inoue T; Ogawa K; Iida K; Tamura N
    J Exp Med; 1987 Nov; 166(5):1221-8. PubMed ID: 2445886
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Biphasic response of complement to heparin: fluid-phase generation of neoantigens in human serum and in a reconstituted alternative pathway amplification cycle.
    Keil LB; Jimenez E; Guma M; Reyes MD; Liguori C; DeBari VA
    Am J Hematol; 1995 Dec; 50(4):254-62. PubMed ID: 7485099
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Analysis of recognition in the alternative pathway of complement. Effect of polysaccharide size.
    Pangburn MK
    J Immunol; 1989 Apr; 142(8):2766-70. PubMed ID: 2467939
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Localization of the complement-component-C3b-binding site and the cofactor activity for factor I in the 38kDa tryptic fragment of factor H.
    Alsenz J; Lambris JD; Schulz TF; Dierich MP
    Biochem J; 1984 Dec; 224(2):389-98. PubMed ID: 6240261
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The separation of functionally distinct forms of the third component of human complement (C3).
    Parkes C; DiScipio RG; Kerr MA; Prohaska R
    Biochem J; 1981 Mar; 193(3):963-70. PubMed ID: 6458280
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Complement C3b interactions studied with surface plasmon resonance technique.
    Jokiranta TS; Westin J; Nilsson UR; Nilsson B; Hellwage J; Löfås S; Gordon DL; Ekdahl KN; Meri S
    Int Immunopharmacol; 2001 Mar; 1(3):495-506. PubMed ID: 11367533
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Role of human factor I and C3b receptor in the cleavage of surface-bound C3bi molecules.
    Medicus RG; Melamed J; Arnaout MA
    Eur J Immunol; 1983 Jun; 13(6):465-70. PubMed ID: 6222909
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Characterization of alternative pathway inhibition by a serum derived, low molecular weight complement inhibitor.
    Baker PJ; Parker CJ; Osofsky SG
    Clin Exp Immunol; 1984 Jan; 55(1):166-76. PubMed ID: 6559107
    [TBL] [Abstract][Full Text] [Related]  

  • 80. C3b generation is affected by the structure of the O-antigen polysaccharide in lipopolysaccharide from salmonellae.
    Jimenez-Lucho VE; Joiner KA; Foulds J; Frank MM; Leive L
    J Immunol; 1987 Aug; 139(4):1253-9. PubMed ID: 2440949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.